ASX Penny Stocks To Watch In July 2026

The Australian stock market is showing signs of optimism, with a 50-point advance expected following positive developments in U.S. bank earnings and consumer prices. Amid these broader economic trends, investors may find opportunities in the realm of penny stocks—companies that, despite their modest price tags and somewhat outdated moniker, continue to hold potential for significant returns when backed by strong financials. This article will explore three such penny stocks that combine balance sheet resilience with the promise of uncovering hidden value.

Let's dive into some prime choices out of the screener.

Aussie Broadband (ASX:ABB)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Aussie Broadband Limited is an Australian company offering telecommunications and technology services, with a market cap of A$1.44 billion.

Operations: The company's revenue is primarily derived from its Residential segment at A$725 million and Wholesale segment at A$79.91 million.

Market Cap: A$1.44B

Aussie Broadband Limited, with a market cap of A$1.44 billion, has shown mixed financial performance. While its short-term assets exceed both short and long-term liabilities, the company experienced negative earnings growth of -10.3% over the past year, contrasting with industry averages. Its debt to equity ratio has increased significantly over five years but remains satisfactorily covered by operating cash flow at 39.1%. Despite a one-off loss impacting recent results and lower net profit margins compared to last year, earnings are forecasted to grow by 30.94% annually, suggesting potential for future recovery in profitability.

• Click to explore a detailed breakdown of our findings in Aussie Broadband's financial health report.
• Learn about Aussie Broadband's future growth trajectory here.

EMVision Medical Devices (ASX:EMV)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: EMVision Medical Devices Ltd focuses on the research, development, and commercialization of neurodiagnostic technology for stroke diagnosis and monitoring, as well as other medical imaging needs in Australia, with a market cap of A$163.60 million.

Operations: The company generates revenue of A$5.43 million from the research and development of medical device technology.

Market Cap: A$163.6M

EMVision Medical Devices Ltd, with a market cap of A$163.60 million, is currently pre-revenue and unprofitable, making it challenging to compare its earnings growth to the industry. However, it maintains strong financial health with short-term assets of A$23.5 million exceeding both short-term (A$1.8M) and long-term liabilities (A$3.4M), and has a sufficient cash runway for over a year despite declining free cash flow rates. While its debt to equity ratio has risen from 0% to 13.6% over five years, the company remains undiluted in shareholder value recently and forecasts revenue growth at 17.89% annually.

• Get an in-depth perspective on EMVision Medical Devices' performance by reading our balance sheet health report here.
• Explore EMVision Medical Devices' analyst forecasts in our growth report.

Perenti (ASX:PRN)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Perenti Limited is a global mining services company with a market capitalization of A$2.03 billion.

Operations: Perenti generates revenue from Drilling Services (A$812.55 million), Contract Mining Services (A$2.48 billion), and Mining and Technology Services (A$217.15 million).

Market Cap: A$2.03B

Perenti Limited, with a market cap of A$2.03 billion, demonstrates solid financial health as its short-term assets (A$1.2 billion) exceed both short-term (A$544 million) and long-term liabilities (A$706.8 million). The company has shown consistent earnings growth over the past five years, although recent growth at 41.1% lags behind industry performance. Perenti's debt is well-managed, with operating cash flow covering 80.4% of its debt and interest payments covered four times by EBIT. Recent board changes include the appointment of Vincent Nicoletti as an independent non-executive director, enhancing strategic leadership in finance and strategy sectors.

• Navigate through the intricacies of Perenti with our comprehensive balance sheet health report here.
• Review our growth performance report to gain insights into Perenti's future.

Turning Ideas Into Actions

• Explore the 405 names from our ASX Penny Stocks screener here.
• Curious About Other Options? These 26 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com